TRANSCON
"TRANSCON" is a word mark owned by Ascendis Pharma A/S, filed at the CIPO on July 25, 2017. It is registered and covers classes 5, 42 and 45.
- Status
- Registered
- Since November 13, 2019
- Filed
- July 25, 2017
- Registered
- November 13, 2019
- Expires
- November 13, 2029
- Application no.
- 1849180
- Registration no.
- TMA1062896
- Office
- CIPO
- Canadian Intellectual Property Office
- Mark type
- Word mark
- 3 classes
Who owns TRANSCON
The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.
Owner
Ascendis Pharma A/S
Denmark
Representative
Smart & Biggar LP
Smart & Biggar LP
What the mark covers
The products and services TRANSCON is filed for, grouped by Nice class.
Pharmaceutical and veterinary preparations, including for physical and mental illness, namely, pharmaceutical preparations for the prevention and treatment of disorders of the endocrine system, namely growth and thyroid disorder, growth hormone deficiency, hypoparathyroidism, achondroplasia, diabetes, fibroblast growth factor receptor(FGFR)-related skeletal disorders, oncology, ophthalmology, infectious diseases and disorders, namely, intestinal infectious diseases, infections with a predominantly sexual mode of transmission, viral infections of the central nervous system, arthropod-borne viral fevers and viral haemorrhagic fevers, viral infections characterized by skin and mucous membrane lesions, human immunodeficiency virus [HIV] disease, mycoses, protozoal diseases, and helminthiases, enzyme replacement therapy, anti-inflammatory disease, the relief of pain, the treatment of chronic pain, the treatment of the musculoskeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, and cartilage injuries, respiratory system disorders, autoimmune disorders, vaccines for human and veterinary use; human and veterinary vaccine preparations, human and veterinary vaccines, non-alcoholic steatohepatitis, psychiatric and other brain diseases and disorders, namely, anxiety, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, and multiple sclerosis, bone diseases, for the treatment of the central nervous system, namely, central nervous system infections, brain diseases, central nervous systems movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy, Parkinson's disease, and brain movement diseases, muscular diseases caused by structural and functional abnormalities of skeletal muscle tissue, namely muscular dystrophies, congenital muscular dystrophies, congenital myopathies, distal myopathies, other myopathies namely, myofibrillar, incusion body, myotonic syndromes, ion channel muscle diseases, malignant hyoperthermias, metabolic myopathies, congenital myasthenic syndromes, sarcopenia, muscle atrophy, cachexia, metabolic diseases of muscle, metabolic myopathies, mintochondria myopathies namely, muscular dystrophy, mucopolysaccharideoses, and cancer, obesity, wound healing, the hormonal system, namely growth hormone deficiency, diabetes and angiogenesis, the ophthalmological system, namely angiogenesis, the angiogenic system, the central nervous system, namely, central nervous system infections, brain diseases, central nervous system movement ; sanitary preparations for medical purposes, namely, sanitizing wipes, disinfectants for medical instruments, adhesive tapes for medical purposes; dietetic substances adapted for medical use, namely, dietetic sugar substitutes adapted for medical use; all-purpose disinfectants for sanitary purposes; fungicides; herbicides
Scientific research within the medical, pharmaceutical and bacteriological area, including consultancy and information relating thereto; conducting of tests regarding medical applications; packaging design for pharmaceutical preparations; designing and development of medical equipment; designing pharmaceutical and medical preparations; preparation of pharmaceutical formulations; design and development of granulation technology and tablet technology, including consultancy and information relating thereto
Licensing of industrial property; legal services
What has happened so far
Steps recorded by the CIPO, newest first.
- Agent Changed; Transferred From: 12 To: 59
- Agent Changed; From: 26 To: 12
- Registered
- Registration Fee Notice Sent
- Registration Pending
- Agent Name Changed
- Advertised; Vol.66 Issue 3377
- Approved; APPROVED BY PROGRAM EX200M1
- Approval Notice Sent
- Examiner's First Report
4 earlier steps on the official record.
About TRANSCON
Who owns the trademark "TRANSCON"?
The CIPO trademark "TRANSCON" (application 1849180) is owned by Ascendis Pharma A/S.
What is the status of "TRANSCON"?
Its status at the CIPO is: registered.
When was "TRANSCON" registered?
It was registered on November 13, 2019 and is due to expire on November 13, 2029.
Get this data via the API
Everything on this page comes from the Signa API. Pull TRANSCON and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019deb6a-c6ee-7487-b9fd-be14b2b633b9
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019deb6a-c6ee-7487-b9fd-be14b2b633b9",
"object": "trademark",
"mark_text": "TRANSCON",
"status": {
"primary": "active",
"stage": "registered"
},
"office_code": "CA",
"application_number": "1849180",
"filing_date": "2017-07-25",
"nice_classes": [
5,
42,
45
],
"owners": [
{
"name": "ASCENDIS PHARMA A/S",
"entity_id": "ent_019eb711-cfef-70e8-9cf4-4a4fa9a981de"
}
]
}